Christopher Mehlin PhD

Dr. Chris Mehlin is Chief Scientific Officer and co-founder of LINK Immunotherapeutics, a role to which he brings over twenty years of drug discovery experience. Chris is an author of over twenty-five publications and is a named inventor on over twenty therapeutic antibody patents, including two (Repatha and Siliq) that have received FDA approval. Before joining LINK, Chris was engaged at the Fred Hutchinson Cancer Research Center (the Hutch), where the foundational technology for LINK was developed and subsequently out-licensed. Prior to Hutch, Chris led a large number of antibody programs at Amgen, integrating the latest in display and transgenic animal technology to develop next-generation therapeutic antibodies.